Developing Nanomedicine that targets cellular heterogeneity for Complete Glioblastoma Remission

Research Project

Project/Area Number	21K12697
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 90120:Biomaterials-related
Research Institution	Kawasaki Institute of Industrial Promotion Innovation Center of NanoMedicine
Principal Investigator	Quader Sabina 公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 主任研究員 (90749699)
Co-Investigator(Kenkyū-buntansha)	藤加珠子公益財団法人川崎市産業振興財団(ナノ医療イノベーションセンター), ナノ医療イノベーションセンター, 研究員 (90342732)
Project Period (FY)	2021-04-01 – 2024-03-31
Project Status	Granted (Fiscal Year 2021)
Budget Amount *help	¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000) Fiscal Year 2023: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000) Fiscal Year 2022: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2021: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	NanoMedicine / Glioblastoma
Outline of Research at the Start	Glioblastoma Multiforme (GBM) is the deadliest human cancer with an average survival at diagnosis of about 1 year. This poor prognosis is partly due to the blood brain tumor barrier (BBTB) that limits drug-delivery to GBM site. Molecular and cellular heterogeneity is another dire challenge in GBM-therapy. In this research we will address the issue of poor drug delivery and tumor heterogeneity of GBM with a specially designed nanomedicine platform to bring total cure of this deadly disease.